Highest-materiality recent filing
Dr. Sian Bigora moves from full-time executive to part-time employee, retains Chief Development and Regulatory Officer title.
Processa's binding term sheet with Intact Therapeutics for PCS12852 expires without deal
Binding Term Sheet dated June 17, 2025 with Intact Therapeutics expired February 12, 2026.
Received Nasdaq notification on January 6, 2026 confirming compliance with Listing Rule 5550(a)(2).
Processa Pharmaceuticals announces 1-for-25 reverse stock split effective Dec 16, 2025
Reverse split reduces outstanding shares 25:1; no change to authorized shares (1B).
Processa shareholders approve 10x authorized share increase and reverse split
Shareholders approved increase in authorized common shares from 100M to 1B (13.7M for, 3.0M against).
Processa shareholders approve 10x increase in authorized shares, reverse split up to 1:50
Approved increase of authorized common shares from 100M to 1B (13.7M for, 3.0M against).
Processa adjourns special meeting; reconvened Sept 11, record date unchanged
Special meeting originally Sept 2 adjourned; now reconvened Sept 11 at 10:30 AM ET in Vero Beach, FL.
Processa special meeting adjourned due to lack of quorum; reconvenes Sept 12
Special shareholder meeting on Sept 2, 2025 adjourned without conducting business because a quorum was not present.
Processa Pharmaceuticals changes 2025 Special Meeting location to Pasadena, CA
Board changed 2025 Special Meeting location from Vero Beach, FL to Pasadena, CA (August 25, 2025).
Processa Pharmaceuticals raises ~$1.3M in private placement; evaluating crypto treasury strategies
Raised ~$1.3M via private placement of 5.47M restricted shares at $0.23/share.
Processa receives second 180-day grace period to regain Nasdaq bid price compliance
Grace period runs until February 2, 2026 to meet $1.00 minimum bid price.
Processa raises $1.3M in private placement; evaluating crypto treasury strategy
Sold 5,467,181 restricted shares at $0.23/share for ~$1.3M gross proceeds.
On July 25, 2025, Processa filed a prospectus supplement to its Form S-3 (Registration No. 333-279588) for an equity distribution agreement with A.G.P./Alliance Global Partners.
All six director nominees elected: Justin Yorke, George Ng, Khoso Baluch, James Neal, Geraldine Pannu, Dr. David Young.
Processa Pharmaceuticals adjourns annual meeting due to lack of quorum; reconvened on July 18, 2025
Annual meeting on June 30, 2025, adjourned due to insufficient quorum; no business conducted.
Terminated licensing agreement with Ocuphire Pharma (now Opus Genetics) for PCS3117, returning rights to original licensor.
Processa amends Yuhan license; annual meeting adjourned for lack of quorum
Amendment No. 1 to License Agreement with Yuhan Corporation effective June 11, 2025, linked to term sheet with Intact Therapeutics dated June 17, 2025.
Processa prices $7M public offering of common stock and warrants at $0.25/unit
Gross proceeds of $7M before expenses; offering of 28M shares/pre-funded warrants plus 28M common warrants.
Near-term payments: $2.5M option exercise fee plus 3.5% equity stake in Intact upon closing.
Processa Pharmaceuticals posts investor presentation; details not available in filing
Regulation FD disclosure of a slide presentation dated February 2025.
Processa receives Nasdaq bid-price deficiency notice; 180 days to regain compliance
Nasdaq notified Processa that common stock bid price closed below $1.00 for 30 consecutive business days.
Processa closes $5M public offering; Series A/B warrants at $0.65 exercise price
Gross proceeds of $5.0M from offering closed Jan 29, 2025; net proceeds for general corporate purposes.
Processa Pharmaceuticals replaces auditor BD & Co. with Cherry Bekaert
BD & Co. resigned Oct 31, 2024 after merger into Citrin Cooperman; no disagreements or reportable events.
First patient dosed in Phase 2 trial (NCT06568692) of NGC-Cap vs capecitabine in 60-90 advanced/metastatic breast cancer patients.
Processa provides pipeline update, Q2 net loss $3.0M; Phase 2 NGC-Cap trial underway
FDA cleared IND for NGC-Cap Phase 2 in July 2024; multicenter trial in metastatic breast cancer initiated, initial data expected mid-2025.
FDA clears IND for Processa's NGC-Cap Phase 2 trial in breast cancer
FDA cleared IND for NGC-Cap Phase 2 trial in advanced/metastatic breast cancer.
Processa appoints Russell Skibsted as CFO; James Stanker retires
Russell Skibsted appointed CFO effective July 16, 2024; succeeds James Stanker who retired.
Processa shareholders elect directors, approve equity plan increase and auditor ratification
All six director nominees (Yorke, Ng, Baluch, Neal, Pannu, Young) elected with over 878K 'For' votes each.
Processa enters ATM equity agreement to sell up to $2.4M in common stock
Sales agreement with A.G.P./Alliance Global Partners for at-the-market offering of up to $2.4 million.
Processa presents NGC-Cap Phase 1b data at AACR; poster modified
David Young, President R&D, presented two abstracts at AACR 2024 on NGC-Cap and Project Optimus.
Processa CEO presents at MedInvest conference; no specific material data in filing
CEO George Ng presented at MedInvest Biotech + Pharma Investor Conference on April 3, 2024 in NYC.
On April 30, 2026, Processa Pharmaceuticals, Inc. (the “Company”) approved a transition in the employment status of Dr. Sian Bigora, the Company’s Chief Development and Regulatory Officer, as part of her planned transition toward retirement.
by mutual agreement, James Stanker resigned as Chief Financial Officer of the Company, effective July 15, 2024.
announced the appointment of Mr. Russell Skibsted, Effective July 16, 2024 as its Chief Financial Officer.
Max materiality 0.80 · Median 0.55 · Most common event other_material